Marinomed Biotech AG expands Carragelose product line in Austria and Mexico for hay fever and viral respiratory infections.
Marinomed Biotech AG expands its Carragelose product portfolio with new launches in Austria and Mexico, targeting new indications and key markets. The company launches a new allergen-blocking nasal spray in Austria for hay fever treatment and partners with M8 Pharmaceuticals to launch a Carragelose nasal spray for viral respiratory infections in Mexico. These launches aim to maximize value and revenue potential for the Carragelose asset.
April 11, 2024
3 Articles